CY1117537T1 - Ποντικια που εκφραζουν μια υβριδικη ελαφρια αλυσιδα της ανοσοσφαιρινης - Google Patents

Ποντικια που εκφραζουν μια υβριδικη ελαφρια αλυσιδα της ανοσοσφαιρινης

Info

Publication number
CY1117537T1
CY1117537T1 CY20161100440T CY161100440T CY1117537T1 CY 1117537 T1 CY1117537 T1 CY 1117537T1 CY 20161100440 T CY20161100440 T CY 20161100440T CY 161100440 T CY161100440 T CY 161100440T CY 1117537 T1 CY1117537 T1 CY 1117537T1
Authority
CY
Cyprus
Prior art keywords
mice expressing
sequences
well
immunoglobulin
sequence
Prior art date
Application number
CY20161100440T
Other languages
Greek (el)
English (en)
Inventor
Lynn Macdonald
Sean Stevens
Cagan Gurer
Andrew J Murphy
Karolina A Hosiawa
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of CY1117537T1 publication Critical patent/CY1117537T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Position Input By Displaying (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
CY20161100440T 2010-06-22 2016-05-20 Ποντικια που εκφραζουν μια υβριδικη ελαφρια αλυσιδα της ανοσοσφαιρινης CY1117537T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35731710P 2010-06-22 2010-06-22
US35731410P 2010-06-22 2010-06-22
EP11728509.8A EP2480676B1 (en) 2010-06-22 2011-06-22 Mice expressing an immunoglobulin hybrid light chain

Publications (1)

Publication Number Publication Date
CY1117537T1 true CY1117537T1 (el) 2017-04-26

Family

ID=44509861

Family Applications (5)

Application Number Title Priority Date Filing Date
CY20161100440T CY1117537T1 (el) 2010-06-22 2016-05-20 Ποντικια που εκφραζουν μια υβριδικη ελαφρια αλυσιδα της ανοσοσφαιρινης
CY20161100585T CY1117692T1 (el) 2010-06-22 2016-06-28 Ποντικια που εκφραζουν μια ελαφρια αλυσιδα με ανθρωπινη λαμδα μεταβλητη και ποντικισια σταθερη περιοχη
CY20161100670T CY1118126T1 (el) 2010-06-22 2016-07-13 Ποντικια που εκφραζουν μια υβριδικη ελαφρια αλυσιδα της ανοσοσφαιρινης με ανθρωπινη μεταβλητη περιοχη
CY20171101102T CY1119478T1 (el) 2010-06-22 2017-10-24 Διαγονιδιακα ποντικια με τροποποιημενο ενδογενη γονιδιακο τοπο λαμδα ανοσοσφαιρινης
CY20191100459T CY1122877T1 (el) 2010-06-22 2019-04-30 Ποντικια που εκφραζουν με υβριδικη ελαφρια αλυσιδα της ανοσοσφαιρινης με ανθρωπινη μεταβλητη περιοχη

Family Applications After (4)

Application Number Title Priority Date Filing Date
CY20161100585T CY1117692T1 (el) 2010-06-22 2016-06-28 Ποντικια που εκφραζουν μια ελαφρια αλυσιδα με ανθρωπινη λαμδα μεταβλητη και ποντικισια σταθερη περιοχη
CY20161100670T CY1118126T1 (el) 2010-06-22 2016-07-13 Ποντικια που εκφραζουν μια υβριδικη ελαφρια αλυσιδα της ανοσοσφαιρινης με ανθρωπινη μεταβλητη περιοχη
CY20171101102T CY1119478T1 (el) 2010-06-22 2017-10-24 Διαγονιδιακα ποντικια με τροποποιημενο ενδογενη γονιδιακο τοπο λαμδα ανοσοσφαιρινης
CY20191100459T CY1122877T1 (el) 2010-06-22 2019-04-30 Ποντικια που εκφραζουν με υβριδικη ελαφρια αλυσιδα της ανοσοσφαιρινης με ανθρωπινη μεταβλητη περιοχη

Country Status (30)

Country Link
US (22) US9012717B2 (enExample)
EP (7) EP3456832A1 (enExample)
JP (16) JP5988969B2 (enExample)
KR (16) KR20220150430A (enExample)
CN (4) CN104342455B (enExample)
AU (1) AU2011271046B2 (enExample)
BR (3) BR112012033248A2 (enExample)
CA (2) CA2804311C (enExample)
CY (5) CY1117537T1 (enExample)
DK (5) DK3034608T3 (enExample)
ES (5) ES2570131T3 (enExample)
HR (5) HRP20160794T1 (enExample)
HU (5) HUE030285T2 (enExample)
IL (12) IL300712B2 (enExample)
LT (4) LT2480675T (enExample)
ME (5) ME03386B (enExample)
MX (6) MX348942B (enExample)
MY (6) MY165287A (enExample)
NO (1) NO2905338T3 (enExample)
NZ (6) NZ626979A (enExample)
PL (5) PL3034608T3 (enExample)
PT (5) PT2480675T (enExample)
RS (5) RS58736B1 (enExample)
RU (3) RU2590594C2 (enExample)
SG (4) SG10201504324UA (enExample)
SI (5) SI2480676T1 (enExample)
SM (5) SMT201700506T1 (enExample)
TR (1) TR201905992T4 (enExample)
WO (2) WO2011163314A1 (enExample)
ZA (5) ZA201300062B (enExample)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
LT2346994T (lt) 2008-09-30 2022-03-10 Ablexis, Llc Knock-in pelė, skirta chimerinių antikūnų gamybai
CN112690250B (zh) 2008-12-18 2024-03-08 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
EP3028565B1 (en) 2009-07-08 2017-09-27 Kymab Limited Animal models and therapeutic molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
SMT201900372T1 (it) 2010-02-08 2019-09-09 Regeneron Pharma Topo con catena leggera comune
KR102004106B1 (ko) 2010-03-31 2019-07-25 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
SI2480676T1 (sl) 2010-06-22 2016-10-28 Regeneron Pharmaceuticals, Inc. Hibridna mišja lahka veriga
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
RU2580017C2 (ru) 2010-07-26 2016-04-10 Трианни, Инк. Трансгенные животные и способы применения
RU2612903C2 (ru) 2010-08-02 2017-03-13 Ридженерон Фармасьютикалз, Инк. Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены
HUE068728T2 (hu) 2011-08-05 2025-01-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
EP2757875B2 (en) 2011-09-19 2023-03-22 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
JP2014531452A (ja) * 2011-09-19 2014-11-27 カイマブ・リミテッド 動物、レパートリーおよび方法
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
MX378871B (es) 2011-12-20 2025-03-10 Regeneron Pharma Ratones con cadena ligera humanizada.
KR102213535B1 (ko) 2012-03-16 2021-02-08 리제너론 파마슈티칼스 인코포레이티드 pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물
EP3348140B1 (en) 2012-03-16 2020-12-30 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
CA2865644A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
WO2013144567A1 (en) 2012-03-28 2013-10-03 Kymab Limited Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
RS57582B1 (sr) 2013-02-20 2018-11-30 Regeneron Pharma Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca
PT3501272T (pt) * 2013-03-13 2023-03-29 Regeneron Pharma Murganhos que expressam um repertório limitado de cadeia leve de imunoglobulina
EP2967012B1 (en) 2013-03-14 2020-09-16 Erasmus University Medical Center Rotterdam Transgenic non-human mammal for antibody production
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
KR102150414B1 (ko) * 2013-09-18 2020-09-02 리제너론 파마슈티칼스 인코포레이티드 히스티딘 엔지니어링된 경쇄 항체 및 그것을 생성하기 위한 유전자 변형된 비-인간 동물
WO2015049517A2 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
WO2015103999A1 (en) * 2014-01-10 2015-07-16 Hung Alfur Fu-Hsin Transgenic animals capable of producing humanized ige at much higher levels than mouse ige
RU2016141307A (ru) 2014-03-21 2018-04-24 Регенерон Фармасьютикалз, Инк. Отличные от человека животные, которые вырабатывают однодоменные связывающие белки
WO2015143406A2 (en) * 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
DK3151921T3 (da) 2014-06-06 2019-12-02 Bristol Myers Squibb Co Antistoffer mod glucocorticoid-induceret tumornekrosefaktor- receptorer (gitr) og anvendelser deraf
KR20170083534A (ko) 2014-09-19 2017-07-18 리제너론 파마슈티칼스 인코포레이티드 키메라 항원 수용체
WO2016054598A2 (en) 2014-10-03 2016-04-07 Massachusetts Institute Of Technology Antibodies that bind ebola glycoprotein and uses thereof
DK3221363T3 (da) 2014-11-21 2020-08-10 Bristol Myers Squibb Co Antistoffer mod cd73 og anvendelser deraf
WO2016097865A1 (en) 2014-12-19 2016-06-23 Regenesance B.V. Antibodies that bind human c6 and uses thereof
SG10202006538TA (en) 2014-12-23 2020-08-28 Bristol Myers Squibb Co Antibodies to tigit
EP3254035B1 (de) 2015-02-05 2019-01-30 Basf Se Solarkraftwerk mit einem ersten wärmeträgerkreislauf und einem zweiten wärmeträgerkreislauf
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
LT3303396T (lt) 2015-05-29 2023-01-10 Bristol-Myers Squibb Company Antikūnai prieš ox40 ir jų panaudojimo būdai
MX2017016502A (es) 2015-06-29 2018-03-12 Univ Rockefeller Anticuerpos contra cd40 con actividad agonista mejorada.
CN105274116B (zh) * 2015-10-21 2020-09-29 重庆金迈博生物科技有限公司 一种制备人源化抗体的核酸分子及其应用
BR112018010172A2 (pt) 2015-11-19 2018-11-21 Bristol Myers Squibb Co anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
WO2017095939A1 (en) 2015-12-03 2017-06-08 Trianni, Inc. Enhanced immunoglobulin diversity
WO2017136734A1 (en) 2016-02-04 2017-08-10 Trianni, Inc. Enhanced production of immunoglobulins
KR20180118725A (ko) 2016-03-04 2018-10-31 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
CA3016534A1 (en) 2016-03-04 2017-09-08 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
EA039084B1 (ru) 2016-05-09 2021-12-01 Бристол-Майерс Сквибб Компани Антитела к tl1a и их применения
WO2017201476A1 (en) 2016-05-20 2017-11-23 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
IL263160B2 (en) 2016-06-03 2024-01-01 Regeneron Pharma Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
WO2017214089A1 (en) 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
US20170372142A1 (en) * 2016-06-27 2017-12-28 Facebook, Inc. Systems and methods for identifying matching content
AU2017297506A1 (en) 2016-07-14 2019-02-21 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
US10981976B2 (en) 2016-08-31 2021-04-20 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
AU2017343778A1 (en) 2016-10-13 2019-05-02 Massachusetts Institute Of Technology Antibodies that bind Zika virus envelope protein and uses thereof
CN109906272A (zh) 2016-10-31 2019-06-18 国立大学法人鸟取大学 产生人抗体的非人动物和使用该非人动物的人抗体制作方法
MA53935A (fr) 2016-11-04 2021-12-22 Regeneron Pharma Animaux non humains ayant un locus à chaîne légère lambda d'immunoglobuline modifiée
KR102573778B1 (ko) 2017-02-17 2023-08-31 브리스톨-마이어스 스큅 컴퍼니 알파-시뉴클레인에 대한 항체 및 그의 용도
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
PL3720279T3 (pl) 2017-12-05 2023-01-16 Regeneron Pharmaceuticals, Inc. Myszy posiadające zmodyfikowany sposobami inżynierii łańcuch lekki lambda immunoglobuliny oraz ich zastosowania
KR102813913B1 (ko) 2018-01-12 2025-05-30 브리스톨-마이어스 스큅 컴퍼니 Tim3에 대한 항체 및 그의 용도
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル－マイヤーズ スクイブ カンパニー Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
SMT202500038T1 (it) 2018-03-24 2025-03-12 Regeneron Pharma Topi o ratti geneticamente modificati per la generazione di anticorpi terapeutici contro complessi peptide-mhc, metodi di produzione e loro utilizzo
KR20250121150A (ko) 2018-03-26 2025-08-11 리제너론 파마슈티칼스 인코포레이티드 치료제를 시험하기 위한 인간화된 설치류
CA3102441C (en) * 2018-06-08 2023-06-13 Crystal Bioscience Inc. Transgenic animal for producing diversified antibodies that have the same light chain i
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
CN112969929B (zh) 2018-10-26 2024-06-21 日本汽车能源株式会社 电池控制装置
TW202033555A (zh) 2018-11-16 2020-09-16 美商必治妥美雅史谷比公司 抗nkg2a抗體及其用途
US11008395B2 (en) 2019-01-22 2021-05-18 Bristol Myers-Squibb Company Antibodies against IL-7R alpha subunit and uses thereof
EP3927153A1 (en) 2019-02-22 2021-12-29 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
CA3136478A1 (en) * 2019-06-05 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
JP7752536B2 (ja) * 2019-07-01 2025-10-10 トリアニ・インコーポレイテッド トランスジェニック哺乳動物およびその使用法
WO2021113297A1 (en) 2019-12-02 2021-06-10 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
JP2023541216A (ja) * 2020-06-25 2023-09-29 ヒューマブ カンパニー リミテッド ヘテロ接合型トランスジェニック動物
EP4211155A1 (en) 2020-09-11 2023-07-19 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
EP4262373A1 (en) 2020-12-16 2023-10-25 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
JP7758739B2 (ja) 2020-12-23 2025-10-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アンカー改変型抗体をコードする核酸およびその使用
AU2021409906A1 (en) 2020-12-23 2023-06-15 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
WO2023199655A1 (ja) 2022-04-13 2023-10-19 日本精工株式会社 軸受装置の状態の検出方法、検出装置、およびプログラム
USD999969S1 (en) * 2022-04-29 2023-09-26 Shenzhen Intellirocks Tech. Co., Ltd. Lamp
WO2024163477A1 (en) 2023-01-31 2024-08-08 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
AU2024265613A1 (en) 2023-05-04 2025-09-25 Novasenta, Inc. Anti-cd161 antibodies and methods of use thereof
US20250361320A1 (en) 2024-02-27 2025-11-27 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69233750D1 (de) 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
DE69738539T2 (de) * 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
CN101498731A (zh) * 2000-05-18 2009-08-05 日本烟草产业株式会社 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DK1354034T3 (da) * 2000-11-30 2008-03-25 Medarex Inc Transgene transchromosomale gnavere til fremstilling af humane antistoffer
GB0031284D0 (en) * 2000-12-21 2001-01-31 Ks Biomedix Ltd High affinity antibodies
DE60227067D1 (de) * 2001-05-11 2008-07-24 Kirin Pharma Kk Künstliches menschliches chromosom mit dem gen für die lambda-leichte kette menschlicher antikörper
GB0115256D0 (en) * 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
US7435871B2 (en) * 2001-11-30 2008-10-14 Amgen Fremont Inc. Transgenic animals bearing human Igλ light chain genes
US20030217171A1 (en) 2002-05-17 2003-11-20 Von Stuermer Wolfgang R. Self-replicating and self-installing software apparatus
MXPA06000562A (es) * 2003-07-15 2006-03-30 Therapeutic Human Polyclonals Loci de inmunoglobulina humanizada.
CN1605628A (zh) * 2003-09-03 2005-04-13 中国疾病预防控制中心病毒病预防控制所 Cho细胞生产的人源抗甲肝病毒基因工程抗体
US7476724B2 (en) * 2004-08-05 2009-01-13 Genentech, Inc. Humanized anti-cmet antibodies
EP1802193B1 (en) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
KR100971497B1 (ko) * 2004-12-29 2010-07-21 주식회사유한양행 인간 종양괴사인자-알파에 특이적으로 결합하는 인간화항체
EP2505058A1 (en) 2006-03-31 2012-10-03 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
JP2010501165A (ja) * 2006-08-22 2010-01-21 ジーツー インフラメイション プロプライエタリー リミテッド 抗体の作製方法
WO2008054606A2 (en) 2006-10-02 2008-05-08 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
US7864492B2 (en) 2006-10-31 2011-01-04 Siemens Industry, Inc. Systems and methods for arc fault detection
DE102007045897A1 (de) 2007-09-26 2009-04-09 Carl Zeiss Microimaging Gmbh Verfahren zur mikroskopischen dreidimensionalen Abbildung einer Probe
EP2271758B1 (en) * 2008-04-14 2018-09-12 Innovative Targeting Solutions Inc. Sequence diversity generation in immunoglobulins
EP2669298A3 (en) * 2008-05-23 2014-02-26 Ablexis, LLC Single variable immunoglobulin domain comprising VL-DH-JL
LT2346994T (lt) * 2008-09-30 2022-03-10 Ablexis, Llc Knock-in pelė, skirta chimerinių antikūnų gamybai
CN112690250B (zh) * 2008-12-18 2024-03-08 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
EP3028565B1 (en) 2009-07-08 2017-09-27 Kymab Limited Animal models and therapeutic molecules
SMT201900372T1 (it) * 2010-02-08 2019-09-09 Regeneron Pharma Topo con catena leggera comune
NZ605966A (en) 2010-06-17 2015-04-24 Kymab Ltd Animal models and therapeutic molecules
SI2480676T1 (sl) * 2010-06-22 2016-10-28 Regeneron Pharmaceuticals, Inc. Hibridna mišja lahka veriga

Also Published As

Publication number Publication date
RS55037B1 (sr) 2016-12-30
DK2568049T3 (en) 2016-08-01
PT2480676E (pt) 2016-06-09
IL259965B (en) 2019-02-28
US20170258059A1 (en) 2017-09-14
SMT201600213B (it) 2016-08-31
NZ707200A (en) 2016-04-29
US9206263B2 (en) 2015-12-08
IL223720A (en) 2017-05-29
JP6073441B2 (ja) 2017-02-01
DK2480676T3 (en) 2016-06-20
EP2480676B1 (en) 2016-04-06
US9150662B2 (en) 2015-10-06
US9066502B2 (en) 2015-06-30
US9035128B2 (en) 2015-05-19
MY195214A (en) 2023-01-11
AU2011271043A8 (en) 2016-01-21
KR20180135997A (ko) 2018-12-21
SI2905338T1 (sl) 2017-12-29
BR112012032991A8 (pt) 2020-09-29
NZ605758A (en) 2014-08-29
RU2724736C2 (ru) 2020-06-25
ES2721749T3 (es) 2019-08-05
HK1168384A1 (zh) 2012-12-28
CN104404050A (zh) 2015-03-11
US20170107484A1 (en) 2017-04-20
CA2804311A1 (en) 2011-12-29
HRP20171666T1 (hr) 2017-12-15
ZA201506598B (en) 2017-03-29
JP2018023403A (ja) 2018-02-15
US9850462B2 (en) 2017-12-26
US9006511B2 (en) 2015-04-14
KR20220150430A (ko) 2022-11-10
CN103068994A (zh) 2013-04-24
WO2011163314A1 (en) 2011-12-29
JP2019033765A (ja) 2019-03-07
US20130326647A1 (en) 2013-12-05
US20130323790A1 (en) 2013-12-05
HRP20160865T1 (hr) 2016-10-07
CA2804311C (en) 2017-09-12
RU2013102595A (ru) 2014-07-27
US20150246976A1 (en) 2015-09-03
KR102211911B1 (ko) 2021-02-05
KR102059909B1 (ko) 2019-12-27
ME02442B (me) 2016-09-20
US20240327785A1 (en) 2024-10-03
BR112012032991B1 (pt) 2021-08-10
IL247386A (en) 2017-07-31
KR20190014578A (ko) 2019-02-12
NZ707198A (en) 2016-04-29
MX2012015300A (es) 2013-05-01
US20120073004A1 (en) 2012-03-22
WO2011163311A1 (en) 2011-12-29
BR122020013427B1 (pt) 2021-08-03
US9540452B2 (en) 2017-01-10
KR20180135996A (ko) 2018-12-21
ZA201404600B (en) 2015-09-30
US9844212B2 (en) 2017-12-19
AU2011271043A1 (en) 2013-01-31
PL2480675T3 (pl) 2017-03-31
PT2568049T (pt) 2016-07-11
IL313063A (en) 2024-07-01
JP6009441B2 (ja) 2016-10-19
RS56589B1 (sr) 2018-02-28
KR102506001B1 (ko) 2023-03-07
KR20200064166A (ko) 2020-06-05
IL223719A (en) 2016-10-31
ME02444B (me) 2016-09-20
MX348942B (es) 2017-07-04
IL300712B1 (en) 2024-07-01
JP6963542B2 (ja) 2021-11-10
US9226484B2 (en) 2016-01-05
KR20230036157A (ko) 2023-03-14
KR20190014576A (ko) 2019-02-12
RU2016119423A (ru) 2018-11-07
US20190203171A1 (en) 2019-07-04
IL291301B1 (en) 2023-03-01
PL2480676T3 (pl) 2016-10-31
IL291301A (en) 2022-05-01
US20150173331A1 (en) 2015-06-25
EP3034608B1 (en) 2019-01-30
SG186390A1 (en) 2013-01-30
IL291301B2 (en) 2023-07-01
IL255179A0 (en) 2017-12-31
MX336344B (es) 2016-01-15
PL3034608T3 (pl) 2019-08-30
RS55042B1 (sr) 2016-12-30
US20150246977A1 (en) 2015-09-03
KR101975884B1 (ko) 2019-05-10
LT3034608T (lt) 2019-05-27
EP2905338B1 (en) 2017-08-02
JP2018201528A (ja) 2018-12-27
EP2480675B1 (en) 2016-04-06
SI2480675T1 (sl) 2016-08-31
CY1122877T1 (el) 2021-05-05
HUE029692T2 (en) 2017-03-28
ME02440B (me) 2016-09-20
KR20190073584A (ko) 2019-06-26
RU2601297C2 (ru) 2016-10-27
MX347318B (es) 2017-04-21
CA2803864C (en) 2017-05-16
IL255179B (en) 2018-06-28
MY194456A (en) 2022-11-30
HRP20190807T1 (hr) 2019-08-23
RS58736B1 (sr) 2019-06-28
US20190153384A1 (en) 2019-05-23
ME03386B (me) 2020-01-20
HK1226766A1 (en) 2017-10-06
US9206262B2 (en) 2015-12-08
IL269078B (en) 2021-05-31
IL282872B (en) 2022-04-01
CY1118126T1 (el) 2017-06-28
KR20210134424A (ko) 2021-11-09
LT2905338T (lt) 2017-12-27
BR112012032991A2 (pt) 2015-10-06
EP2480675A1 (en) 2012-08-01
KR20190049932A (ko) 2019-05-09
CN104342455B (zh) 2017-05-31
EP2480676A1 (en) 2012-08-01
ZA201404601B (en) 2016-02-24
NO2905338T3 (enExample) 2017-12-30
IL244450A0 (en) 2016-04-21
NZ605751A (en) 2014-10-31
JP2018201527A (ja) 2018-12-27
KR20190142436A (ko) 2019-12-26
KR102320944B1 (ko) 2021-11-04
SI3034608T1 (sl) 2019-06-28
AU2011271043A9 (en) 2015-10-01
KR101991234B1 (ko) 2019-06-20
CY1119478T1 (el) 2018-03-07
IL282872A (en) 2021-06-30
JP2013531501A (ja) 2013-08-08
HUE036597T2 (hu) 2018-07-30
JP2023133554A (ja) 2023-09-22
SMT201600212B (it) 2016-08-31
ES2575223T3 (es) 2016-06-27
IL264634B (en) 2019-09-26
JP6243384B2 (ja) 2017-12-06
KR101970944B1 (ko) 2019-04-23
US9334333B2 (en) 2016-05-10
JP2020128440A (ja) 2020-08-27
CN103068993B (zh) 2016-01-06
EP2568049A1 (en) 2013-03-13
TR201905992T4 (tr) 2019-05-21
JP2016010417A (ja) 2016-01-21
MY195212A (en) 2023-01-11
CN104342455A (zh) 2015-02-11
US9399683B2 (en) 2016-07-26
ES2646052T3 (es) 2017-12-11
RU2590594C2 (ru) 2016-07-10
AU2011271043B2 (en) 2015-10-01
PT2480675T (pt) 2016-07-11
PL2905338T3 (pl) 2018-01-31
US9206261B2 (en) 2015-12-08
JP2020062061A (ja) 2020-04-23
ZA201300062B (en) 2014-09-25
MY157477A (en) 2016-06-15
US20140137275A1 (en) 2014-05-15
DK2480675T3 (en) 2016-08-01
KR102193823B1 (ko) 2020-12-22
SG10201504324UA (en) 2015-07-30
KR20130121814A (ko) 2013-11-06
LT2568049T (lt) 2016-10-10
HUE030285T2 (en) 2017-05-29
US9012717B2 (en) 2015-04-21
EP3456832A1 (en) 2019-03-20
JP2017006152A (ja) 2017-01-12
CY1117692T1 (el) 2017-05-17
US20150173332A1 (en) 2015-06-25
IL269078A (en) 2019-11-28
CN103068993A (zh) 2013-04-24
JP2025027148A (ja) 2025-02-26
EP2905338B8 (en) 2018-01-24
US20150351371A1 (en) 2015-12-10
MX2022002117A (es) 2022-03-17
US9029628B2 (en) 2015-05-12
DK3034608T3 (da) 2019-05-06
IL259965A (en) 2018-07-31
JP7236409B2 (ja) 2023-03-09
JP6545773B2 (ja) 2019-07-17
RU2016119423A3 (enExample) 2019-11-19
JP2016010415A (ja) 2016-01-21
EP2568049B1 (en) 2016-04-13
KR101945352B1 (ko) 2019-02-07
AU2011271046A1 (en) 2013-01-31
HK1183321A1 (en) 2013-12-20
JP2021061863A (ja) 2021-04-22
US20160057979A1 (en) 2016-03-03
SI2568049T1 (sl) 2016-10-28
EP3205726A1 (en) 2017-08-16
EP3034608A1 (en) 2016-06-22
EP2905338A1 (en) 2015-08-12
KR102266097B1 (ko) 2021-06-18
PT2905338T (pt) 2017-11-10
CN104404050B (zh) 2018-06-08
KR102118565B1 (ko) 2020-06-03
HK1170766A1 (zh) 2013-03-08
DK2905338T3 (da) 2017-11-06
KR20210013376A (ko) 2021-02-03
JP2013532974A (ja) 2013-08-22
JP2022066449A (ja) 2022-04-28
NZ626979A (en) 2015-05-29
PL2568049T3 (pl) 2017-03-31
KR102462042B1 (ko) 2022-11-03
US20160060359A1 (en) 2016-03-03
MY165287A (en) 2018-03-21
MX347322B (es) 2017-04-21
US10266803B2 (en) 2019-04-23
US20180064078A1 (en) 2018-03-08
BR112012033248A2 (pt) 2017-11-28
LT2480675T (lt) 2016-10-10
RU2013102596A (ru) 2014-07-27
US9394373B2 (en) 2016-07-19
US20150176002A1 (en) 2015-06-25
KR20200143511A (ko) 2020-12-23
CN103068994B (zh) 2016-01-20
SG10201504568YA (en) 2015-07-30
US9163092B2 (en) 2015-10-20
ZA201300063B (en) 2014-09-25
ME02902B (me) 2018-04-20
IL300712B2 (en) 2024-11-01
RS54891B1 (sr) 2016-10-31
SMT201900241T1 (it) 2019-05-10
KR20210073609A (ko) 2021-06-18
HUE044001T2 (hu) 2019-09-30
KR101934852B1 (ko) 2019-01-04
US20150320023A1 (en) 2015-11-12
US20200239837A1 (en) 2020-07-30
JP5988969B2 (ja) 2016-09-07
HUE029691T2 (en) 2017-03-28
US20120070861A1 (en) 2012-03-22
SG186391A1 (en) 2013-01-30
MY195217A (en) 2023-01-11
NZ627119A (en) 2015-05-29
ES2570131T3 (es) 2016-05-17
SI2480676T1 (sl) 2016-10-28
MX2012015298A (es) 2013-05-01
ES2576928T3 (es) 2016-07-12
HRP20160497T1 (hr) 2016-07-15
PT3034608T (pt) 2019-05-28
SMT201600229B (enExample) 2016-08-31
US20150089680A1 (en) 2015-03-26
IL300712A (en) 2023-04-01
CA2803864A1 (en) 2011-12-29
HRP20160794T1 (hr) 2016-08-12
KR20130027555A (ko) 2013-03-15
AU2011271046B2 (en) 2015-10-01
SMT201700506T1 (it) 2018-01-11
JP2017012204A (ja) 2017-01-19
JP6341972B2 (ja) 2018-06-13
KR102001430B1 (ko) 2019-07-18
IL244450A (en) 2017-11-30

Similar Documents

Publication Publication Date Title
CY1117537T1 (el) Ποντικια που εκφραζουν μια υβριδικη ελαφρια αλυσιδα της ανοσοσφαιρινης
CY1126091T1 (el) Adam6 ποντικια
CY1121223T1 (el) Ποντικοι οι οποιοι εκφραζουν ανθρωποποιημενο μειζον συμπλεγμα ιστοσυμβατοτητας
CY1121869T1 (el) Ποντικοι με γενετικα τροποποιημενο μειζον συμπλεγμα ιστοσυμβατοτητας
CY1121545T1 (el) Ποντικοι που εκφραζουν περιορισμενο ρεπερτοριο ελαφριων αλυσιδων ανοσοσφαιρινης
CY1122463T1 (el) Αγωγη των κυτταρων παθησεων cd47+ με συντηξεις sirp αλφα-fc
CY1119283T1 (el) Γενετικα τροποποιημενοι ποντικοι εκφραζοντες χιμαιρικα μορια μειζονος συμπλεγματος ιστοσυμβατοτητας (mhc) ii
CY1120770T1 (el) Ζωα πλην του ανθρωπου με τροποποιημενες αλληλουχιες βαριας αλυσιδας της ανοσοσφαιρινης
CY1125474T1 (el) Μη ανθρωπινα ζωα με τροποποιημενο τοπο ελαφριας αλυσιδας λαμδα ανοσοσφαιρινης
CY1117606T1 (el) Μη ανθρωπινα ζωα που εκφραζουν αντισωματα τα οποια εχουν μια κοινη ελαφρια αλυσιδα
CY1119219T1 (el) Anti-ceacam5 αντισωματα και χρησεις αυτων
CY1120414T1 (el) Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους
MX2012009168A (es) Raton de cadena ligera comun.
PE20211291A1 (es) Anticuerpos anti-ox40 y metodos de uso
BR112016005912A2 (pt) sequência de ácido nucleico de cadeia leve de imunoglobulina recombinante, animal não humano geneticamente modificado, métodos para gerar um anticorpo e uma proteína de ligação e para produzir um animal não humano, célula ou tecido, vetor de alvejamento, proteína de ligação, e, ácido nucleico
CY1120123T1 (el) Μονοκλωνικα αντισωματα κατα της gt468 για τη θεραπεια του καρκινου
CY1121055T1 (el) Μεθοδος για την παρασκευη φορτισμενων διασυνδετων
MX374756B (es) Organizacion de vector de expresion, metodos novedosos de generacion de celulas de produccion y su uso para la produccion recombinante de polipeptidos.
PH12016500742A1 (en) Novel peptide having 4 linked ctl epitopes
TH146784A (th) หนูที่แสดงออกสายเบาไฮบริดของอิมมูโนโกลบูลิน
CY1121329T1 (el) Πολυσθενες μοριο δεσμευσhς αντιγονου fv
CY1116725T1 (el) Μεταλλαγμενη διαυλοροδοψινη 2